Traws Pharma (TRAW) Competitors $4.48 -0.21 (-4.48%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.79 +0.31 (+6.92%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRAW vs. SKYE, DBVT, IMUX, CTOR, GALT, INZY, ABOS, ENTX, XFOR, and CLLSShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Skye Bioscience (SKYE), DBV Technologies (DBVT), Immunic (IMUX), Citius Oncology (CTOR), Galectin Therapeutics (GALT), Inozyme Pharma (INZY), Acumen Pharmaceuticals (ABOS), Entera Bio (ENTX), X4 Pharmaceuticals (XFOR), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Skye Bioscience DBV Technologies Immunic Citius Oncology Galectin Therapeutics Inozyme Pharma Acumen Pharmaceuticals Entera Bio X4 Pharmaceuticals Cellectis Traws Pharma (NASDAQ:TRAW) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking. Do analysts rate TRAW or SKYE? Skye Bioscience has a consensus target price of $18.67, indicating a potential upside of 523.26%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, TRAW or SKYE? Traws Pharma has higher revenue and earnings than Skye Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$230K71.10-$18.95M-$141.56-0.03Skye BioscienceN/AN/A-$37.65MN/AN/A Do institutionals & insiders have more ownership in TRAW or SKYE? 8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 13.6% of Traws Pharma shares are owned by insiders. Comparatively, 3.0% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is TRAW or SKYE more profitable? Skye Bioscience has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma-62,294.25% N/A -822.38% Skye Bioscience N/A -45.78%-37.44% Does the media refer more to TRAW or SKYE? In the previous week, Traws Pharma and Traws Pharma both had 2 articles in the media. Traws Pharma's average media sentiment score of 0.00 equaled Skye Bioscience'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, TRAW or SKYE? Traws Pharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Does the MarketBeat Community favor TRAW or SKYE? Traws Pharma and Skye Bioscience both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformTraws PharmaN/AN/ASkye BioscienceN/AN/A SummarySkye Bioscience beats Traws Pharma on 7 of the 11 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.35M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.036.1326.4618.82Price / Sales71.10313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book0.356.747.634.64Net Income-$18.95M$138.11M$3.18B$245.69M7 Day Performance-27.86%-2.43%-1.91%-2.66%1 Month Performance-21.68%-1.91%-0.19%-2.15%1 Year PerformanceN/A-5.03%16.70%12.90% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.539 of 5 stars$4.48-4.5%N/AN/A$17.12M$230,000.000.0017News CoverageGap DownSKYESkye Bioscience1.2618 of 5 stars$3.17+15.9%$18.67+489.8%-52.1%$90.41MN/A0.0011Gap UpDBVTDBV Technologies3.6764 of 5 stars$4.39+0.9%$22.50+412.5%-45.9%$90.30M$15.73M-0.9880Analyst ForecastIMUXImmunic2.3124 of 5 stars$1.00+4.5%$12.67+1,166.7%-1.7%$90.08MN/A-0.8170Analyst ForecastNews CoverageGap UpCTORCitius OncologyN/A$1.25-2.3%$3.00+140.0%N/A$89.44MN/A0.00N/AEarnings ReportNews CoverageGALTGalectin Therapeutics1.6451 of 5 stars$1.41+8.5%$11.00+680.1%-19.9%$88.49MN/A-1.939INZYInozyme Pharma2.983 of 5 stars$1.37+1.5%$18.33+1,238.2%-77.7%$88.01MN/A-0.8850News CoverageABOSAcumen Pharmaceuticals2.4449 of 5 stars$1.45-0.7%$9.33+543.7%-58.4%$87.12MN/A-1.0520ENTXEntera Bio3.0086 of 5 stars$2.43+6.1%$10.00+311.5%+100.0%$86.95M$130,000.00-9.3520Positive NewsXFORX4 Pharmaceuticals4.3594 of 5 stars$0.51+1.2%$3.50+588.3%-46.2%$86.73MN/A-5.6580Gap UpCLLSCellectis2.7552 of 5 stars$1.55+1.3%$7.00+351.6%-46.5%$86.15M$9.19M-1.19290Analyst ForecastGap Up Related Companies and Tools Related Companies Skye Bioscience Competitors DBV Technologies Competitors Immunic Competitors Citius Oncology Competitors Galectin Therapeutics Competitors Inozyme Pharma Competitors Acumen Pharmaceuticals Competitors Entera Bio Competitors X4 Pharmaceuticals Competitors Cellectis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRAW) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
